{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:47Z","timestamp":1786987067560,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clnu.2023.11.009","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T19:20:06Z","timestamp":1699989606000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers"],"prefix":"10.1016","volume":"43","author":[{"given":"Zhang","family":"Lilong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrui","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clnu.2023.11.009_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clnu.2023.11.009_bib2","article-title":"Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clnu.2023.11.009_bib3","article-title":"The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.clnu.2023.11.009_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"Boku","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clnu.2023.11.009_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12967-021-02937-9","article-title":"PD-1\/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort","volume":"19","author":"Santini","year":"2021","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clnu.2023.11.009_bib6","article-title":"The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.clnu.2023.11.009_bib7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.clnu.2023.11.009_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110200","article-title":"The use of antibiotics during immune checkpoint inhibitor treatment is associated with lower survival in advanced esophagogastric cancer","volume":"119","author":"Zhang","year":"2023","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.clnu.2023.11.009_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110019","article-title":"Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: a pooled analysis of 44 retrospective sudies","volume":"118","author":"Zhang","year":"2023","journal-title":"Int Immunopharm"},{"issue":"1","key":"10.1016\/j.clnu.2023.11.009_bib10","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1080\/21655979.2021.1951522","article-title":"Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma","volume":"12","author":"Ren","year":"2021","journal-title":"Bioengineered"},{"issue":"3","key":"10.1016\/j.clnu.2023.11.009_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.clnu.2023.11.009_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clnu.2023.11.009_bib13","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","article-title":"Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy","volume":"28","author":"Bozzetti","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clnu.2023.11.009_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.clnu.2023.11.009_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clnu.2023.11.009_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12885-023-10582-2","article-title":"Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis","volume":"23","author":"Luo","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clnu.2023.11.009_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10120-018-0882-2","article-title":"Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis","volume":"22","author":"Kamarajah","year":"2019","journal-title":"Gastric Cancer"},{"issue":"10","key":"10.1016\/j.clnu.2023.11.009_bib18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00384-018-3128-1","article-title":"Can sarcopenia be a predictor of prognosis for patients with non-metastatic colorectal cancer? A systematic review and meta-analysis","volume":"33","author":"Sun","year":"2018","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.clnu.2023.11.009_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.949511","article-title":"Impact of skeletal muscle loss during conversion therapy on clinical outcomes in lavage cytology positive patients with gastric cancer","volume":"12","author":"Ding","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.clnu.2023.11.009_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232371","article-title":"Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma","volume":"15","author":"Lanza","year":"2020","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.clnu.2023.11.009_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246355","article-title":"Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (ncscl) treated with immune checkpoint inhibitors (ICIs): a prospective study","volume":"13","author":"Tenuta","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.clnu.2023.11.009_bib22","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00432-020-03146-5","article-title":"Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors","volume":"146","author":"Takada","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.clnu.2023.11.009_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4111\/icu.20220028","article-title":"Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: a retrospective study","volume":"63","author":"Ueki","year":"2022","journal-title":"Investig Clin Urol"},{"issue":"5","key":"10.1016\/j.clnu.2023.11.009_bib24","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/jcsm.12755","article-title":"Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis","volume":"12","author":"Takenaka","year":"2021","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2023.11.009_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101398","article-title":"Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: a new paradigm beyond sarcopenia","volume":"70","author":"Ahn","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.clnu.2023.11.009_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102839","article-title":"Myosteatosis and prognosis in cancer: systematic review and meta-analysis","volume":"145","author":"Aleixo","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.clnu.2023.11.009_bib27","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1007\/s00330-020-07294-7","article-title":"Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy","volume":"31","author":"Peng","year":"2021","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.clnu.2023.11.009_bib28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00330-022-08980-4","article-title":"Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma","volume":"33","author":"Chen","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clnu.2023.11.009_bib29","article-title":"Sarcopenia and systemic inflammation response index predict response to systemic therapy for hepatocellular carcinoma and are associated with immune cells","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clnu.2023.11.009_bib30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1186\/s12885-022-09823-7","article-title":"Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study","volume":"22","author":"Xiao","year":"2022","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.clnu.2023.11.009_bib31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/jgh3.12777","article-title":"Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients","volume":"6","author":"Toshida","year":"2022","journal-title":"JGH Open"},{"key":"10.1016\/j.clnu.2023.11.009_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221142417","article-title":"Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor","volume":"15","author":"Guo","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"issue":"6","key":"10.1016\/j.clnu.2023.11.009_bib33","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00262-020-02794-3","article-title":"Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab","volume":"70","author":"Kim","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.clnu.2023.11.009_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/COC.0000000000000787","article-title":"Impact of sarcopenia, BMI, and inflammatory biomarkers on survival in advanced hepatocellular carcinoma treated with anti-PD-1 antibody","volume":"44","author":"Akce","year":"2021","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clnu.2023.11.009_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000528005","article-title":"Prognostic impact of hepatic steatosis evaluated by CT on immunotherapy for gastric cancer: associations with sarcopenia, systemic inflammation, and hormones","volume":"101","author":"Hayano","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.clnu.2023.11.009_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1061044","article-title":"Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.clnu.2023.11.009_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10120-020-01124-x","article-title":"Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors","volume":"24","author":"Kim","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.clnu.2023.11.009_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.701668","article-title":"Prognostic impact of sarcopenia and radiotherapy in patients with advanced gastric cancer treated with anti-PD-1 antibody","volume":"12","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clnu.2023.11.009_bib39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10147-020-01833-4","article-title":"Association between skeletal muscle loss and the response to nivolumab immunotherapy in advanced gastric cancer patients","volume":"26","author":"Kano","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clnu.2023.11.009_bib40","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.21873\/anticanres.14734","article-title":"Cancer cachexia reduces the efficacy of nivolumab treatment in patients with advanced gastric cancer","volume":"40","author":"Fujii","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clnu.2023.11.009_bib41","article-title":"Sarcopenia: molecular regulatory network for loss of muscle mass and function","volume":"10","author":"Wu","year":"2023","journal-title":"Front Nutr"},{"key":"10.1016\/j.clnu.2023.11.009_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ebiom.2019.10.034","article-title":"Skeletal muscle as potential central link between sarcopenia and immune senescence","volume":"49","author":"Nelke","year":"2019","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.clnu.2023.11.009_bib43","doi-asserted-by":"crossref","first-page":"E453","DOI":"10.1152\/ajpendo.00553.2012","article-title":"Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications","volume":"304","author":"Pillon","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.clnu.2023.11.009_bib44","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.clnu.2023.11.009_bib45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.maturitas.2016.11.006","article-title":"Inflammation and sarcopenia: a systematic review and meta-analysis","volume":"96","author":"Bano","year":"2017","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.clnu.2023.11.009_bib46","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1634\/theoncologist.2019-0751","article-title":"Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy","volume":"25","author":"Bilen","year":"2020","journal-title":"Oncol"},{"issue":"8","key":"10.1016\/j.clnu.2023.11.009_bib47","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clnu.2023.11.009_bib48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2015.03.015","article-title":"Inflammation induced loss of skeletal muscle","volume":"80","author":"Londhe","year":"2015","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.clnu.2023.11.009_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2005.10.049","article-title":"Inflammatory markers and loss\u00a0of\u00a0muscle mass (sarcopenia) and strength","volume":"119","author":"Schaap","year":"2006","journal-title":"Am J Med"},{"issue":"17","key":"10.1016\/j.clnu.2023.11.009_bib50","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.clnu.2023.11.009_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1515\/hsz-2017-0217","article-title":"TGF-\u03b2 requires the activation of canonical and non-canonical signalling pathways to induce skeletal muscle atrophy","volume":"399","author":"\u00c1brigo","year":"2018","journal-title":"Biol Chem"},{"issue":"5","key":"10.1016\/j.clnu.2023.11.009_bib52","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jcsm.12441","article-title":"Tumour-derived transforming growth factor-\u03b2 signalling contributes to fibrosis in patients with cancer cachexia","volume":"10","author":"Lima","year":"2019","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"issue":"7693","key":"10.1016\/j.clnu.2023.11.009_bib53","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.clnu.2023.11.009_bib54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jcsm.12180","article-title":"Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer","volume":"8","author":"Rutten","year":"2017","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561423003667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561423003667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T01:14:37Z","timestamp":1759367677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561423003667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0261561423003667"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2023.11.009","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2023.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}